Ilmarinen Mutual Pension Insurance Co Acquires 8,500 Shares of Merck & Co., Inc. $MRK

Ilmarinen Mutual Pension Insurance Co increased its stake in Merck & Co., Inc. (NYSE:MRK) by 2.0% during the fourth quarter, HoldingsChannel reports. The firm owned 441,500 shares of the company’s stock after acquiring an additional 8,500 shares during the period. Ilmarinen Mutual Pension Insurance Co’s holdings in Merck & Co., Inc. were worth $46,472,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Moors & Cabot Inc. raised its position in shares of Merck & Co., Inc. by 6.2% in the fourth quarter. Moors & Cabot Inc. now owns 97,972 shares of the company’s stock valued at $10,313,000 after purchasing an additional 5,726 shares during the period. EagleClaw Capital Managment LLC boosted its stake in Merck & Co., Inc. by 0.4% in the 4th quarter. EagleClaw Capital Managment LLC now owns 31,963 shares of the company’s stock worth $3,364,000 after purchasing an additional 120 shares during the period. Investment Partners LTD. boosted its stake in Merck & Co., Inc. by 2.1% in the 4th quarter. Investment Partners LTD. now owns 5,021 shares of the company’s stock worth $529,000 after purchasing an additional 103 shares during the period. Houlihan Financial Resource Group Ltd. purchased a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $453,000. Finally, Carnegie Lake Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 2.6% in the fourth quarter. Carnegie Lake Advisors LLC now owns 9,064 shares of the company’s stock worth $954,000 after purchasing an additional 232 shares during the period. Institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MRK. Cantor Fitzgerald boosted their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. UBS Group boosted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Finally, Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $119.87 on Friday. The firm has a market cap of $296.05 billion, a price-to-earnings ratio of 33.77, a price-to-earnings-growth ratio of 2.71 and a beta of 0.18. The business has a 50-day simple moving average of $116.31 and a two-hundred day simple moving average of $111.41. Merck & Co., Inc. has a fifty-two week low of $75.40 and a fifty-two week high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck shareholders approved the company’s board nominees, executive pay package, and auditor ratification at its annual meeting, reinforcing governance continuity and removing a potential overhang. Merck Shareholders Back Board, Pay and Auditor Ratification
• Positive Sentiment: Merck announced participation in the Jefferies Global Healthcare Conference, which can spark investor attention if management provides updates on pipeline progress, guidance, or strategic priorities. Merck to Participate in the Jefferies Global Healthcare Conference
• Positive Sentiment: Merck’s chicken bronchitis vaccine was approved for use in China, expanding a potential animal-health opportunity in a large market and adding a modest growth catalyst. Merck chicken bronchitis vaccine approved for use in China
• Neutral Sentiment: Merck congratulated Ontario on expanding pharmacy scope rules, a policy development that is favorable for healthcare access but has no immediate direct financial impact on MRK. Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care
• Neutral Sentiment: Merck remained a heavily watched stock in Zacks coverage and on analyst/market screens, but those mentions were not tied to a new fundamental development. Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
• Neutral Sentiment: The company’s upcoming Jefferies appearance and shareholder-call materials may keep attention on the stock, but they do not yet signal a clear change in earnings outlook. Merck & Co., Inc. (MRK) Shareholder/Analyst Call – Slideshow

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.